JP2005508617A - プロバイオティックビフィドバクテリウム株類 - Google Patents

プロバイオティックビフィドバクテリウム株類 Download PDF

Info

Publication number
JP2005508617A
JP2005508617A JP2003515648A JP2003515648A JP2005508617A JP 2005508617 A JP2005508617 A JP 2005508617A JP 2003515648 A JP2003515648 A JP 2003515648A JP 2003515648 A JP2003515648 A JP 2003515648A JP 2005508617 A JP2005508617 A JP 2005508617A
Authority
JP
Japan
Prior art keywords
bifidobacterium
bifidobacterium strain
disease
formulation
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003515648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508617A5 (enExample
Inventor
コリンズ，ジョン，ケビン
オサリバン，ジェラルド，クリストファー
オマホニー，リアム
シャナハン，ファーガス
キーリー，バリー
Original Assignee
アリメンタリー・ヘルス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリメンタリー・ヘルス・リミテッド filed Critical アリメンタリー・ヘルス・リミテッド
Publication of JP2005508617A publication Critical patent/JP2005508617A/ja
Publication of JP2005508617A5 publication Critical patent/JP2005508617A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/02—Acetobacter

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
JP2003515648A 2001-07-26 2002-07-26 プロバイオティックビフィドバクテリウム株類 Withdrawn JP2005508617A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IE20010710 2001-07-26
IE20010717 2001-07-26
IE20010714 2001-07-26
IE20010713 2001-07-26
IE20010711 2001-07-26
IE20010709 2001-07-26
PCT/IE2002/000110 WO2003010297A1 (en) 2001-07-26 2002-07-26 Probiotic bifidobacterium strains

Publications (2)

Publication Number Publication Date
JP2005508617A true JP2005508617A (ja) 2005-04-07
JP2005508617A5 JP2005508617A5 (enExample) 2006-01-05

Family

ID=27547373

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003515648A Withdrawn JP2005508617A (ja) 2001-07-26 2002-07-26 プロバイオティックビフィドバクテリウム株類

Country Status (12)

Country Link
US (2) US20030092163A1 (enExample)
EP (1) EP1409644A1 (enExample)
JP (1) JP2005508617A (enExample)
CN (1) CN1561387A (enExample)
AU (1) AU2002329006A1 (enExample)
BR (1) BR0211442A (enExample)
CA (1) CA2454803A1 (enExample)
IL (1) IL160048A0 (enExample)
IN (1) IN2004KN00093A (enExample)
MX (1) MXPA04000738A (enExample)
PE (1) PE20030284A1 (enExample)
WO (1) WO2003010297A1 (enExample)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516405A (ja) * 2003-01-31 2006-07-06 プロビ エービー グルタミン産生能を有する新規のＢｉｆｉｄｏｂａｃｔｅｒｉｕｍ菌株
WO2007058027A1 (ja) 2005-11-18 2007-05-24 Idemitsu Kosan Co., Ltd. バチルス・チューリンゲンシスを含む有害菌の防除剤
WO2007122885A1 (ja) 2006-03-31 2007-11-01 Morinaga Milk Industry Co., Ltd. インターロイキン産生調節剤、該インターロイキン産生調節剤を含む医薬組成物及び飲食品、並びにその製造方法
WO2008088008A1 (ja) * 2007-01-17 2008-07-24 Meiji Dairies Corporation 消化管機能異常症予防及び／又は治療剤
JP2008532532A (ja) * 2005-03-16 2008-08-21 アクティアル・ファルマセウティカ・ソシエダデ・ポル・クオタス・デ・レスポンサビリダデ・リミターダ サワードウの製造における少なくとも６種の乳酸菌および／またはビフィズス菌の混合物
JP2008535861A (ja) * 2005-04-08 2008-09-04 ザ プロクター アンド ギャンブル カンパニー ヒトの美しさの利益のための経口投与されたプロバイオティクビフィズス菌の使用方法
JP2009517374A (ja) * 2005-11-26 2009-04-30 メディカル リサーチ カウンシル プロスタグランジンｅおよび顆粒球マクロファージコロニー刺激因子の投与による創傷治癒の促進
JP2010522552A (ja) * 2007-03-28 2010-07-08 アリメンタリー・ヘルス・リミテッド プロバイオティック性のビフィドバクテリウム菌株
JP2010522553A (ja) * 2007-03-28 2010-07-08 アリメンタリー・ヘルス・リミテッド プロバイオティック性のビフィドバクテリウム菌株
JP2016529309A (ja) * 2013-09-06 2016-09-23 ソファル ソチエタ ペル アツィオニ 酪酸、葉酸、又はナイアシンの腸内産生を増加させるための、及び／又はコハク酸の腸内産生を低下させるための、微生物を含む組成物の使用
JP2020508672A (ja) * 2017-02-28 2020-03-26 アリメンタリー・ヘルス・リミテッド 呼吸器ウイルス感染症に対する免疫応答を有利に調節することができるビフィドバクテリウム・ロンガム
US11400124B2 (en) 2016-05-13 2022-08-02 Sofar S.P.A. Use of probiotics for improving protein absorption
US11464814B2 (en) 2014-04-23 2022-10-11 Sofar Spa Topical composition for use in the treatment of inflammatory bowel disease
US11590179B2 (en) 2017-02-28 2023-02-28 Precisionbiotics Group Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
US11591416B2 (en) 2016-12-02 2023-02-28 Sofar S.P.A. Exopolysaccharides and uses thereof
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
US11752179B2 (en) 2016-06-08 2023-09-12 Alfasigma S.P.A. Medical use of probiotics
US11896631B2 (en) 2016-12-16 2024-02-13 Alfasigma S.P.A. Probiotics for use in the treatment of diverticulosis and diverticular disease
US12589124B2 (en) 2020-03-13 2026-03-31 Precisionbiotics Group Limited Bifidobacterium longum

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7182943B2 (en) * 2002-05-15 2007-02-27 UNIVERSITé LAVAL Method and system for modulation of microbial cell characteristics
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
EP2280286A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
WO2005030230A1 (en) * 2003-09-30 2005-04-07 Probiomics Limited Compositions and methods for treatment or prevention of psoriasis and related disorders
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
AU2004275438B2 (en) * 2003-10-01 2008-05-29 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
US8871266B2 (en) 2003-10-01 2014-10-28 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
US20090257993A1 (en) 2003-12-17 2009-10-15 M Rabet Laura Lactic Acid Producing Bacteria and Lung Function
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
WO2005072718A1 (ja) * 2004-01-28 2005-08-11 Kurume University 乳清発酵物を含有する医薬組成物
JP2005247780A (ja) * 2004-03-05 2005-09-15 Masakazu Maruyama ウイルス性肝炎治療剤
ES2262418B1 (es) * 2004-12-28 2007-11-01 Consejo Superior Investig. Cientificas Extractos proteicos con amplio espectro de actividad antibacteriana y cepas del genero bifidobacterium que los producen.
TW200700074A (en) * 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
AU2011205121B2 (en) * 2005-04-08 2012-07-05 Alimentary Health Ltd Method of use of orally administered probiotic bifidobacteria for human beauty benefits
DE602006006997D1 (de) * 2005-05-16 2009-07-09 Univ Liege Probiotische bifidobacterium arten
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080118473A1 (en) * 2006-11-01 2008-05-22 The Procter & Gamble Company Methods of treating a respiratory condition comprising probiotic treatment
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
US9408818B2 (en) * 2007-02-28 2016-08-09 Mead Johnson Nutrition Company Method for the utilization of and product containing inactivated probiotic
EP1992351B1 (en) 2007-05-18 2016-05-11 Nestec S.A. Lactobacillus johnsonii for prevention of postsurgical infection
ES2523575T3 (es) 2007-06-27 2014-11-27 Laboratorios Ordesa, S.L. Una nueva cepa de bifidobacterium y peptidos acitvos contra infecciones por rotavirus
EP2065048A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
ES2343499B1 (es) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
EP3181134B1 (en) * 2009-06-19 2019-10-30 DuPont Nutrition Biosciences ApS Bifidobacteria for treating diabetes and related conditions
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP2289527B1 (en) * 2009-08-25 2018-02-21 Nestec S.A. Bifidobacterium longum and functional GI disorders
EP2485744A4 (en) * 2009-10-09 2014-01-22 Prothera Inc COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED
PL2498789T3 (pl) 2009-11-11 2017-01-31 Alimentary Health Limited Probiotyczny szczep bifidobacterium
WO2011148220A1 (en) 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving transepithelial resistance
WO2011148219A1 (en) 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving the enteric nervous system
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
ES2389547B1 (es) * 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
EP2651423B1 (en) 2010-12-17 2015-09-30 Compagnie Gervais Danone Lactococcus lactis strains for use in improving digestive condition
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
CN102899261B (zh) * 2011-03-11 2016-12-07 光晟生物科技股份有限公司 长双歧杆菌长亚种br022菌株的用途
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN110055320A (zh) * 2012-03-17 2019-07-26 加州大学评议会 痤疮的快速诊断和个体化治疗
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US20150209468A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism
CA2936110A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Web comprising a microorganism-containing fibrous element and method for making same
US20150209392A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Filaments Comprising a Microorganism and Method for Making Same
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
CN114159476A (zh) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
CN114366759A (zh) 2015-05-22 2022-04-19 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
US20160354507A1 (en) 2015-06-07 2016-12-08 The Procter & Gamble Company Article of commerce containing absorbent article
EP3662917A1 (en) 2015-06-15 2020-06-10 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
US20170020750A1 (en) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch containing microorganism
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
EP3448398A4 (en) 2016-04-21 2019-12-18 Naked Biome, Inc. COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN110996917A (zh) 2017-05-26 2020-04-10 克雷斯顿沃控股公司 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
KR20200038506A (ko) 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
US20190298783A1 (en) * 2018-03-28 2019-10-03 Morinaga Milk Industry Co., Ltd. Composition for relieving stress, pharmaceutical composition and food and drink composition and method for relieving stress using the composition for relieving stress
CN108570434A (zh) * 2018-05-10 2018-09-25 苏州博悦曼环保科技有限公司 高效降解餐厨垃圾的复合菌剂及其制造方法
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
CN109929773B (zh) * 2019-01-10 2020-06-19 江苏德禧生物科技有限公司 一株可用于富硒培养的双歧杆菌及其活性蛋白和应用
CN111411093B (zh) * 2019-04-30 2021-10-22 中国科学院天津工业生物技术研究所 活性提高的磷酸转酮酶及在生产代谢物中的应用
WO2021016081A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
CN116083327B (zh) * 2023-04-07 2023-06-09 天赋能(天津)功能食品研究发展有限公司 长双歧杆菌婴儿亚种及在缓解便秘、抗结肠组织炎症和改善肠道菌群方面的应用
CN116574659A (zh) * 2023-06-14 2023-08-11 江南大学 一株可缓解类风湿性关节炎的长双歧杆菌婴儿亚种及其应用
CN119162041A (zh) * 2024-09-30 2024-12-20 内蒙古农业大学 青春双歧杆菌b-201及其活性物质的后生元制备和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516405A (ja) * 2003-01-31 2006-07-06 プロビ エービー グルタミン産生能を有する新規のＢｉｆｉｄｏｂａｃｔｅｒｉｕｍ菌株
JP2011172590A (ja) * 2005-03-16 2011-09-08 Actial Farmaceutica Soc Por Quotas De Responsabilidade Ltda サワードウの製造における少なくとも６種の乳酸菌および／またはビフィズス菌の混合物
JP2008532532A (ja) * 2005-03-16 2008-08-21 アクティアル・ファルマセウティカ・ソシエダデ・ポル・クオタス・デ・レスポンサビリダデ・リミターダ サワードウの製造における少なくとも６種の乳酸菌および／またはビフィズス菌の混合物
JP4808768B2 (ja) * 2005-03-16 2011-11-02 アクティアル・ファルマセウティカ・ソシエダデ・ポル・クオタス・デ・レスポンサビリダデ・リミターダ サワードウの製造における少なくとも６種の乳酸菌および／またはビフィズス菌の混合物
JP2008535861A (ja) * 2005-04-08 2008-09-04 ザ プロクター アンド ギャンブル カンパニー ヒトの美しさの利益のための経口投与されたプロバイオティクビフィズス菌の使用方法
WO2007058027A1 (ja) 2005-11-18 2007-05-24 Idemitsu Kosan Co., Ltd. バチルス・チューリンゲンシスを含む有害菌の防除剤
JP2009517374A (ja) * 2005-11-26 2009-04-30 メディカル リサーチ カウンシル プロスタグランジンｅおよび顆粒球マクロファージコロニー刺激因子の投与による創傷治癒の促進
WO2007122885A1 (ja) 2006-03-31 2007-11-01 Morinaga Milk Industry Co., Ltd. インターロイキン産生調節剤、該インターロイキン産生調節剤を含む医薬組成物及び飲食品、並びにその製造方法
JP4979689B2 (ja) * 2006-03-31 2012-07-18 森永乳業株式会社 インターロイキン産生調節剤、該インターロイキン産生調節剤を含む医薬組成物及び飲食品、並びにその製造方法
WO2008088008A1 (ja) * 2007-01-17 2008-07-24 Meiji Dairies Corporation 消化管機能異常症予防及び／又は治療剤
JPWO2008088008A1 (ja) * 2007-01-17 2010-05-13 明治乳業株式会社 消化管機能異常症予防及び／又は治療剤
CN101646444B (zh) * 2007-01-17 2013-11-06 株式会社明治 功能性胃肠病预防和/或治疗剂
US9675647B2 (en) 2007-01-17 2017-06-13 Meiji Co., Ltd. Prophylactic and/or therapeutic agent for functional gastrointestinal disorders
JP2010522553A (ja) * 2007-03-28 2010-07-08 アリメンタリー・ヘルス・リミテッド プロバイオティック性のビフィドバクテリウム菌株
JP2010522552A (ja) * 2007-03-28 2010-07-08 アリメンタリー・ヘルス・リミテッド プロバイオティック性のビフィドバクテリウム菌株
JP2016529309A (ja) * 2013-09-06 2016-09-23 ソファル ソチエタ ペル アツィオニ 酪酸、葉酸、又はナイアシンの腸内産生を増加させるための、及び／又はコハク酸の腸内産生を低下させるための、微生物を含む組成物の使用
US11839634B2 (en) 2013-09-06 2023-12-12 Alfasigma S.P.A. Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid
US11464814B2 (en) 2014-04-23 2022-10-11 Sofar Spa Topical composition for use in the treatment of inflammatory bowel disease
US11400124B2 (en) 2016-05-13 2022-08-02 Sofar S.P.A. Use of probiotics for improving protein absorption
US11752179B2 (en) 2016-06-08 2023-09-12 Alfasigma S.P.A. Medical use of probiotics
US11591416B2 (en) 2016-12-02 2023-02-28 Sofar S.P.A. Exopolysaccharides and uses thereof
US11896631B2 (en) 2016-12-16 2024-02-13 Alfasigma S.P.A. Probiotics for use in the treatment of diverticulosis and diverticular disease
JP2020508672A (ja) * 2017-02-28 2020-03-26 アリメンタリー・ヘルス・リミテッド 呼吸器ウイルス感染症に対する免疫応答を有利に調節することができるビフィドバクテリウム・ロンガム
JP7055814B2 (ja) 2017-02-28 2022-04-18 プリシジョンバイオティクス・グループ・リミテッド 呼吸器ウイルス感染症に対する免疫応答を有利に調節することができるビフィドバクテリウム・ロンガム
US11529381B2 (en) 2017-02-28 2022-12-20 Precisionbiotics Group Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
US11590179B2 (en) 2017-02-28 2023-02-28 Precisionbiotics Group Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
US12589124B2 (en) 2020-03-13 2026-03-31 Precisionbiotics Group Limited Bifidobacterium longum

Also Published As

Publication number Publication date
IN2004KN00093A (enExample) 2006-03-03
CN1561387A (zh) 2005-01-05
IL160048A0 (en) 2004-06-20
WO2003010297A1 (en) 2003-02-06
EP1409644A1 (en) 2004-04-21
PE20030284A1 (es) 2003-05-01
MXPA04000738A (es) 2004-07-08
US20060121015A1 (en) 2006-06-08
BR0211442A (pt) 2004-11-09
CA2454803A1 (en) 2003-02-06
US20030092163A1 (en) 2003-05-15
AU2002329006A1 (en) 2003-02-17

Similar Documents

Publication Publication Date Title
JP4415164B2 (ja) プロバイオティック・ラクトバチラス・サリバリウス株
JP2005508150A (ja) プロバイオティックラクトバチラスカゼイ株類
US20030092163A1 (en) Probiotic bifidobacterium strains
RU2466185C2 (ru) ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, ПРОБИОТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЯ ШТАММА Bifidobacterium longum
AU2015200833B2 (en) Probiotic bifidobacterium strain
JP5538209B2 (ja) プロバイオティック性のビフィドバクテリウム菌株
AU2002329007A1 (en) "Probiotic Lactobacillus salivarius strains"
RU2302458C2 (ru) Пробиотический штамм lactobacillus salivarius (варианты), пробиотический препарат на их основе и способ лечения или предупреждения с использованием штаммов lactobacillus salivarius
ZA200400555B (en) Probiotic bifidobacterium strains.
IE20020626A1 (en) Probiotic Bifidobacterium strains
AU2002328131A1 (en) Probiotic lactobacillus casei strains
IE20020624A1 (en) Probiotic Lactobacillus casei strains
ZA200400556B (en) Probiotic lactobacillus salivarius strains.
ZA200400557B (en) Probiotic lactobacillus casei strains.
IE20020620A1 (en) Probiotic Lactobacillus salivarius strains
HK1242734A1 (en) Probiotic bifidobacterium strain
IE86045B1 (en) Probiotic bifidobacteria strains
IE20080245A1 (en) Probiotic Bifidobacteria strains

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050627

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070126